<DOC>
	<DOCNO>NCT01034189</DOCNO>
	<brief_summary>We hypothesize addition cetuximab twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy ( TP-CCRT ) adjunctive therapy esophagectomy definitive CRT would improve therapeutic efficacy TP-CCRT patient loco-regional esophageal squamous cell carcinoma ( ESCC ) .</brief_summary>
	<brief_title>Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed Esophagectomy Loco-regional Esophageal Cancer</brief_title>
	<detailed_description>We hypothesize addition cetuximab twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy adjunctive therapy esophagectomy definitive CRT would improve therapeutic efficacy TP-CCRT patient loco-regional esophageal squamous cell carcinoma .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Pathologically proven squamous cell carcinoma esophagus . 2 . Locoregional disease , define TNM system American Joint Committee Cancer ( AJCC ) Cancer Staging System ( 6th edition ) 2002 , fulfil one follow criterion : A. T3 , N0 , M0 ; B. T13 , N1 , M0 ; C. T13 N01 , M1a eligible provide lesion could cover appropriate radiation field . 3 . Age ≥ 18 year old . 4 . Performance status ECOG 0~2 . 5 . Adequate bone marrow reserve , define : A. white blood cell ( WBC ) ≥ 4,000/µl neutrophil count ( ANC ) ≥ 2,000/µl ; B. platelets ≥ 100,000/µl . 6 . Adequate liver function reserve , define : A. hepatic transaminase ≤ 2.5 x upper limit normal ( ULN ) ; B. serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . 7 . Adequate renal function : Creatinine ≤1.5 mg/dl 8 . Written informed consent . 1 . Invasion surround organ ( T4 disease ) . 2 . Distant metastasis , except M1a disease list inclusion criterion 2C . 3 . Adenocarcinoma gastroesophageal ( GE ) junction . 4 . Prior thoracic irradiation . 5 . Synchronously diagnose squamous cell carcinoma aerodigestive way , esophageal cancer . 6 . Prior malignancy , except follow : A. adequately treat basal cell squamous cell skin cancer ; B. insitu cervical cancer ; C. Note : previously treat aerodigestive squamous cell carcinoma allow . 7 . Significant comorbid disease , prohibit conduction chemotherapy , concurrent chemoradiotherapy , radical surgery , active systemic infection , symptomatic cardiac pulmonary disease , psychiatric disorder . 8 . Estimated life expectancy le 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cetuximab</keyword>
</DOC>